Our Computer Vision and Deep Learning algorithms enable remote measurement and monitoring of neurological disorders using oculometric data captured with a standard webcam or smartphone.
NeuraLight aims to transform neurological diagnosis, patient monitoring, clinical development, and precision care with objective and sensitive digital oculometric biomarkers. We’re starting with clinical drug development and introducing robust, sensitive measures.
These markers serve as a reliable proxy for currently used clinical endpoints, and taken together, provide an accurate snapshot of a patient’s neurological status.
Through our various collaborations with pharma companies and clinical centers, and our own independent research, we are rapidly building the world’s largest de-identified database of oculometric data for people with various neurological disorders and healthy controls.
The Eye as a
Window to the Brain
Our goal is to improve accuracy of clinical trials, expedite timelines, facilitate distributed trials, increase probability of success, minimize misdiagnosis, and enable precision care with low-burden measures for both patients and clinical teams.
Central Nervous System (CNS) drug development suffers from 3 main pain points:
The principal reason is the lack of objective and sensitive endpoints, precluding insightful study designs and smart patient selection. These factors force large (and hence expensive) trials due to high variability, and extend the duration of trials due to low sensitivity.
NeuraLight's digital oculometric markers enable pharma companies to:
Our Computer Vision and Deep Learning algorithms enable remote measurement and monitoring of neurological disorders using oculometric data captured with a standard webcam or smartphone.